Novo NordiskNVO
About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 76,302
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
6% more call options, than puts
Call options by funds: $1.28B | Put options by funds: $1.21B
0.07% more ownership
Funds ownership: 9.87% [Q3] → 9.94% (+0.07%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 588 | Existing positions reduced: 639
7% less funds holding
Funds holding: 1,765 [Q3] → 1,634 (-131) [Q4]
24% less capital invested
Capital invested by funds: $39.6B [Q3] → $30.1B (-$9.52B) [Q4]
31% less first-time investments, than exits
New positions opened: 197 | Existing positions closed: 285
49% less funds holding in top 10
Funds holding in top 10: 61 [Q3] → 31 (-30) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
BMO Capital Evan David Seigerman 28% 1-year accuracy 5 / 18 met price target | 4%downside $64 | Market Perform Downgraded | 17 Apr 2025 |
Financial journalist opinion
Based on 88 articles about NVO published over the past 30 days
